The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients

JACC: Heart Failure

Volumn 1, Issue 1, 2013, Pages 72-78

  Hall, Philip S ^a   Harshman, Lauren C ^a   Srinivas, Sandy ^a   Witteles, Ronald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Heart failure; Hypertension; Tyrosine kinase inhibitor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; HEART LEFT VENTRICLE FUNCTION; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84877995039     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.09.001     Document Type: Article

References (29)

1. Lenihan D.J. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?. J Clin Oncol 2008, 26:5154-5155.
2. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, CD003917.
3. Zuppinger C., Suter T.M. Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J Cardiovasc Pharmacol 2010, 56:141-146.
4. Molina A.M., Motzer R.J. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011, 16(Suppl 2):45-50.
5. Wong M.K., Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 2009, 29:473-478.
6. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
7. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
8. Richards C.J., Je Y., Schutz F.A., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011, 29:3450-3456.
9. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
10. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19:1613-1618.
11. Orphanos G.S., Ioannidis G.N., Ardavanis A.G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009, 48:964-970.
12. Sunitinib prescribing information. Pfizer, New York, NY. Available at: Accessed November 3, 2012. http://www.pfizer.com/pfizer/download/uspi_sutent.pdf.
13. Rock E.P., Goodman V., Jiang J.X., et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12:107-113.
14. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
15. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105:986-993.
16. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
17. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
18. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513.
19. Witteles R.M., Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned?. J Clin Oncol 2012, 30:1916-1918.
20. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 US Department of Health and Human Services, NIH. Bethesda, MD: June 14, 2010; Publication No. 09-5410.
21. Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29:632-638.
22. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
23. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
24. Hasinoff B.B., Patel D., O'Hara K.A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 2008, 74:1722-1728.
25. Hasinoff B.B., Patel D. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 2010, 10:1-8.
26. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
27. Cheitlin M.D., Alpert J.S., Armstrong W.F., et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol 1997, 42:954-970.
28. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-90.
29. Herceptin prescribing information. Available at: Accessed November 3, 2012. http://www.herceptin.com/pdf/herceptin-prescribing.pdf.